Merck & Co.
Merck Completes $10 Billion Acquisition of Verona Pharma, Gaining COPD Drug Ohtuvayre Merck completed its acquisition of...
Elevance Health
Elevance Health Reports Strong Fourth Quarter and Full Year 2024 Results; Sets Ambitious 2025 Outlook Elevance Health reported operating revenue of $1...
Cencora
Cencora Completes Acquisition of Retina Consultants of America Cencora announced the completion of its acquisition of ap...
Complete Rankings
Elevance Health Reports Strong Fourth Quarter and Full Year 2024 Results; Sets Ambitious 2025 Outlook Elevance Health reported operating revenue of $175.2 billion for 2024, an increase of $5.0 billion or 3%, while serving approximately 112 million consumers. Fourth quarter profits fell to $418 million from $856 million year-over-year amid higher Medicaid costs. The company set 2025 outlook with adjusted EPS guidance of $34.15-$34.85 and projected Medicare Advantage growth of 7-9% to 2.2-2.5 mill
Merck Completes $10 Billion Acquisition of Verona Pharma, Gaining COPD Drug Ohtuvayre Merck completed its acquisition of UK-based Verona Pharma for approximately $10 billion, with Verona becoming a wholly-owned subsidiary. The transaction brings Ohtuvayre (ensifentrine), a first-in-class selective dual inhibitor of PDE3 and PDE4 approved by the FDA in June 2024 for maintenance treatment of chronic obstructive pulmonary disease in adults. This represents Merck's largest acquisition since the $10.
Cencora Completes Acquisition of Retina Consultants of America Cencora announced the completion of its acquisition of approximately 85% interest in Retina Consultants of America (RCA) for $4.4 billion in cash, subject to post-closing adjustments. RCA is a leading management services organization of retina specialists, and the acquisition advances Cencora's specialty leadership in physician-administered treatments. Certain RCA physicians and members of the management team retained a minority equi
Cooper Companies Reports Record Fiscal 2024 Results with $3.90 Billion Revenue The Cooper Companies announced record fourth quarter and full-year 2024 results with fiscal year revenue of $3.90 billion, up 8% organically. Q4 revenue reached $1.018 billion, up 10% year-over-year. GAAP diluted EPS was $1.96 (up 33%) and non-GAAP diluted EPS was $3.69 (up 15%). CEO Al White stated that fiscal 2024 was a great year having achieved record consolidated revenues across both CooperVision and CooperSurgic
IQVIA and NVIDIA Collaborate to Transform Healthcare Through Advanced Agentic AI Solutions IQVIA announced strategic collaboration with NVIDIA to help realize the potential of AI in healthcare and life sciences. The partnership will accelerate IQVIA Healthcare-grade AI™ using NVIDIA AI Foundry service to build custom foundation models and agentic AI workflows that automate complex processes across the therapeutic lifecycle. IQVIA will leverage its unparalleled information assets and domain exper
Boston Scientific Reports Record 2024 Results with 17.6% Revenue Growth Boston Scientific announced record fourth quarter and full year 2024 financial results, with annual revenue of $16.75 billion representing 17.6% growth year-over-year. Fourth quarter net sales reached $4.561 billion, up 22.4% on a reported basis. CEO Mike Mahoney stated '2024 was one of the best years in the history of Boston Scientific,' highlighting strong performance across all business segments.
Intuitive Announces da Vinci 5 FDA Clearance - Fifth-Generation Robotic System The FDA cleared Intuitive's next-generation da Vinci 5 multiport robotic system featuring Force Feedback technology, over 10,000x the computing power of previous systems, and enhanced ergonomics. The revolutionary system enables surgeons to measure and feel subtle forces exerted on tissue during surgery, representing the biggest generational leap in da Vinci technology evolution.
Medtronic Reports Fiscal 2025 Results: $33.5 Billion Revenue, Plans Diabetes Separation Medtronic reported fiscal year 2025 worldwide revenue of $33.537 billion, a 3.6% increase year-over-year, with non-GAAP diluted EPS of $5.49, up 6% (10% constant currency). The company announced plans for its Diabetes business to become fully independent and provided fiscal 2026 guidance for approximately 5% organic revenue growth, demonstrating continued momentum.
HCA Healthcare Reports Fourth Quarter and Full Year 2024 Results HCA Healthcare announced Q4 2024 revenues of $18.285 billion with net income of $1.438 billion ($5.63 per share), including $0.60 per share hurricane impact. Full year revenues reached $70.603 billion with net income of $5.760 billion ($22.00 per share), up 9.9% from 2023. The company provided 2025 guidance targeting $74.3 billion in revenue and $6.1 billion in net income.
IDEXX Launches Revolutionary Cancer Dx Early Detection Panel IDEXX announced the launch of IDEXX Cancer Dx, a first-of-its-kind affordable diagnostic panel with early detection of canine lymphoma available for as low as $15. The breakthrough blood test can be integrated into annual wellness screenings and diagnostic panels, addressing the critical need for accessible cancer screening in the 20 million higher-risk dogs in North America.
Pfizer Completes Acquisition of Metsera for $7 Billion Pfizer completed its acquisition of Metsera for $65.60 per share in cash, representing approximately $7.0 billion in enterprise value, plus contingent value rights up to $20.65 per share. The acquisition added a portfolio of GLP-1 and weight management candidates including MET-097i entering Phase 3 development, MET-233i monthly amylin analog, and an oral GLP-1 RA in Phase 1.
Bristol Myers Squibb Reports Strong Fourth Quarter and Full-Year 2024 Financial Results BMS announced Q4 and full-year 2024 results showing revenues of $48.3 billion, up 7% year-over-year (9% adjusting for FX). The Growth Portfolio reached $22.6 billion with 17% growth. Eliquis generated $13.3 billion, Opdivo $9.2 billion, and the new product portfolio grew 77% to $3.6 billion led by Reblozyl, Opdualag, Breyanzi, and Cobenfy.
Edwards Lifesciences Reports Strong Q4 and Full Year 2024 Results Edwards Lifesciences announced full year 2024 revenue of $5.44 billion, representing 8.6% growth. Q4 2024 sales grew 9% to $1.39 billion with strength across all product groups, including 6% TAVR growth and 88% TMTT growth to $105 million. The company demonstrated strong profitability with net margins of 22.8% and announced record cash flow generation.
Insulet Reports Full Year 2024 Revenue Increase of 22% and Surpasses 500,000 Global Customers Insulet announced record full-year 2024 revenue of $2.07 billion, representing 22% growth year-over-year, marking the ninth consecutive year of 20%+ constant currency revenue growth. The company surpassed 500,000 global customers with 365,000 active Omnipod 5 users, achieved 69.8% gross margin and 14.9% operating margin.
Danaher Reports Fourth Quarter and Full Year 2024 Results Danaher announced Q4 2024 revenues increased 2.0% year-over-year to $6.5 billion with non-GAAP core revenue up 1.0%. Full year 2024 revenues were $23.9 billion (flat YoY) with operating cash flow of $6.7 billion and free cash flow of $5.3 billion. The company provided 2025 guidance with full year core revenue expected to increase approximately 3%.
Lilly Reports Full Q4 2024 Financial Results and Provides 2025 Guidance Eli Lilly announced exceptional Q4 2024 results with worldwide revenue of $13.53 billion (up 45%) and full year revenue of $45.04 billion (up 32%). Net income was $4.41 billion with EPS of $4.88. The company provided 2025 revenue guidance of $58.0-61.0 billion, representing continued strong growth driven by Mounjaro and Zepbound.
Incyte Appoints Bill Meury as Chief Executive Officer Incyte announced the appointment of Bill Meury as President and CEO, succeeding Hervé Hoppenot who retired after 11 years of leadership. Meury brings extensive pharmaceutical experience from his roles as CEO of Anthos Therapeutics and Karuna Therapeutics, and as Chief Commercial Officer at Allergan. Julian Baker was elected Chairman of the Board.
Henry Schein Reports Fourth Quarter and Full Year 2024 Financial Results Henry Schein reported Q4 2024 non-GAAP diluted EPS of $1.19 and full-year revenue of $12.7 billion, up 2.7% from 2023. Operating cash flow reached $848 million, up $348 million from prior year. The company provided 2025 guidance for non-GAAP EPS of $4.80-$4.94 and announced completion of its 2022-2024 BOLD+1 Strategic Plan.
Cardinal Health Completes Acquisition of Integrated Oncology Network Cardinal Health completed the acquisition of Integrated Oncology Network, expanding its Navista oncology practice alliance. The acquisition strengthens Cardinal Health's position in specialty pharmaceutical services for community oncologists, helping boost patient outcomes and lower treatment costs in value-based care models.
Quest Diagnostics and Epic Collaborate to Transform Laboratory Testing Experience Quest Diagnostics and Epic announced an industry-first collaboration designed to streamline experiences for healthcare providers and patients. Epic will deliver technologies and services for Project Nova, Quest's multi-year initiative to simplify customer-facing processes and improve laboratory testing workflows.
Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024 Hologic reported strong Q4 fiscal 2024 results with revenue of $987.9 million and non-GAAP EPS of $1.01, concluding the year with $4.03 billion in total revenue. The company demonstrated 4.5% total revenue growth in Q4 and maintained strong cash flow generation with $367.1 million in operating cash flow for the quarter.
Baxter Appoints Andrew Hider as President and CEO Baxter International announced the appointment of Andrew Hider as president and CEO, effective no later than September 3, 2025. Hider previously served as CEO of ATS since 2017, where he led the company's revenues to nearly double and saw stock price more than triple, bringing proven operational excellence to Baxter's transformation.
Biogen Reports Fourth Quarter and Full Year 2024 Results Biogen reported full year 2024 revenue of $9.7 billion (down 2% YoY) with GAAP diluted EPS of $11.18 (up 40% YoY). Q4 2024 revenue reached $2.5 billion with 3% growth. LEQEMBI generated approximately $87 million in Q4 global sales, and SKYCLARYS booked $102 million in Q4 sales, nearly double the year-earlier period.
Agilent Reports Strong Q4 Fiscal Year 2025 Financial Results Agilent reported Q4 2025 revenue of $1.86 billion, representing 9.4% reported growth and 7.2% core growth. Full-year FY2025 revenue reached $6.95 billion. The Life Sciences and Diagnostics Markets Group showed exceptional performance with Q4 revenue of $755 million, up 15% reported and 11% core year-over-year.
Gilead's Yeztugo Wins FDA Approval as First Twice-Yearly HIV Prevention The FDA approved Yeztugo (lenacapavir) for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 in adults and adolescents. This marks the first and only twice-yearly HIV PrEP option available in the United States, reviewed under priority review designation.
GE HealthCare Reports Strong Fourth Quarter and Full Year 2024 Results GE HealthCare reported Q4 2024 revenue of $5.3B (up 2%) and full-year revenue of $19.7B (up 1%), with adjusted EBIT margin expanding to 16.3% from 15.1%. Net income margin improved to 10.1% from 8.0%, demonstrating strong profitability growth and operational excellence.
Bio-Techne Reports Record Q2 Fiscal 2025 Results with 9% Organic Revenue Growth Bio-Techne announced second quarter fiscal 2025 results with organic revenue increasing 9% to $297 million. The company demonstrated strong performance across its portfolio and reaffirmed its commitment to innovation in spatial biology and diagnostic solutions.
BD Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results BD announced Q4 fiscal 2025 revenue of $5.9 billion with 8.3% reported growth and 3.9% organic growth, bringing full-year revenue to $21.8 billion, an increase of 8.2%. The Board of Directors declared a quarterly dividend of $1.05 per common share, a 1.0% increase.
Mettler-Toledo Reports Strong Q4 2024 Results with 12% Sales Growth Mettler-Toledo announced fourth quarter 2024 results with reported and local currency sales increasing 12% year-over-year to $1.045 billion, and adjusted EPS of $12.41, a 32% increase over the prior-year amount of $9.40, demonstrating strong operational performance.
DaVita Celebrates 25 Years of Exceptional Patient Care DaVita celebrated 25 years since forming with a purpose 'to give life' in 2000, highlighting a quarter-century of clinical care delivery, leadership in healthcare innovation, and commitment to improving clinical outcomes and quality of life for kidney disease patients worldwide.
Moderna Reports Q4 2024 Results, Provides 2025 Guidance Moderna reported full-year 2024 revenue of $3.24 billion and provided 2025 guidance of $1.5-2.5 billion. The company announced accelerated cost reduction programs projecting $1.0 billion in savings for 2025 and outlined plans to deliver up to 10 product approvals through 2027.
Dexcom Expands ŌURA Partnership with Stelo Integration Dexcom officially launched integration between its Stelo over-the-counter CGM and the Oura Ring, giving users 24/7 glucose insights via the Oura app. This expansion builds on the November 2024 strategic partnership and $75 million investment in ŌURA.
Labcorp Announces 2024 Fourth Quarter and Full Year Results Labcorp reported full year 2024 revenue of $13.01 billion, up 6.97% from 2023. Q4 revenue reached $3.33 billion. The company completed $839 million in acquisitions during 2024 and provided 2025 revenue guidance of $13.88-14.05 billion.
Align Technology Reaches 20 Million Invisalign Patient Milestone In Q1 2025, Align Technology reached the significant milestone of 20 million Invisalign patients treated worldwide, demonstrating the global adoption and success of clear aligner orthodontics across 280,000+ trained doctors.